Neuren Pharmaceuticals Limited (ASX:NEU)

Market Cap	2.86B +31.8%
Revenue (ttm)	64.65M -70.2%
Net Income	30.44M -78.6%
EPS	0.23 -78.6%
Shares Out	126.77M
PE Ratio	96.82
Forward PE	61.49
Dividend	n/a
Ex-Dividend Date	n/a

Volume	632,758
Open	22.50
Previous Close	22.53
Day's Range	20.26 - 22.92
52-Week Range	11.00 - 23.76
Beta	1.59
Analysts	Strong Buy
Price Target	25.34 (+24.64%)
Earnings Date	Aug 26, 2026

About Neuren Pharmaceuticals

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid; and in Phase 2 clinical trial for the treatment of Angelman and Pitt Hopkins. In addition, it develo...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 8
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: NEU

Financial Performance

In 2025, Neuren Pharmaceuticals's revenue was 64.65 million, a decrease of -70.18% compared to the previous year's 216.83 million. Earnings were 30.44 million, a decrease of -78.57%.

Analyst Summary

According to 6 analysts, the average rating for NEU stock is "Strong Buy." The 12-month stock price target is $25.34, which is an increase of 24.64% from the latest price.

Price Target

$25.34

(24.64% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 26, 2026

Data Sources Report a data error